As a strategic consultant and biotech analyst, Karen is hired by her clients to ensure that expert doctors (key opinion leaders), attorneys, corporate marketers, board members, and investors are all on the same page in regard to what is being said about a product and a disease state. She has been brought in to turn around situations where her clients were looking to dissolve strategic business units ranging from $200mm - $350mm because they were facing up to a billion-dollar fine or simply losing too much revenue. One turnaround resulted in a $1B+ exit acquisition strategy for Mallinckrodt.
Her clients have included Pfizer, Medtronic, Allergan, Johnson & Johnson, Thermo Fisher Scientific and many smaller companies.
She has worked with venture capital firms to reposition portfolio companies from private portfolio VC firms to Johnson & Johnson Development Corporation. She was an interim CMO for a publicly traded immune supplement company and understands the requirements to disclose material contracts and matters that have the potential to affect profits and revenues/EPS. She is well versed in contract law for a lay person, having run her own marketing and consulting firm for several years, Varitage, and managing both employee as well as spokesperson contracts at other firms and organizations. The law firms she has worked with include Wilson Sonsini GoodRich (WSGR), Greenburg Traurig Law (GT Law), Rutan & Tucker, et al.
Karen Kingston left her lucrative career in #BigPharma after being called by God to use her knowledge and skill set to tell the world the details of the dangerous corruption plaguing medical establishments, government, and media.
Since then, she has been physically assaulted, deplatformed, defamed, and spends countless hours doing research so that you can have lifesaving information. If you would like to help Karen, please click the link below.
Copyright © 2023 Karen Kingston - All Rights Reserved.
Stay Ahead of the Narrative. The Kingston Report presents evidence-based breaking news on the COVID-19 Industry before any other media outlet.